Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX replaces the missing or deficient factor IX in the intrinsic pathway of the coagulation cascade. Once infused, it binds to factor VIIIa on activated platelets and catalyzes the conversion of factor X to Xa, leading to thrombin generation and fibrin clot formation, thereby restoring normal hemostasis.

The dose of Immunine is individualized and set by the prescribing physician based on the patient’s weight, severity of factor IX deficiency, target plasma activity level, and the clinical situation (e.g., on‑demand treatment versus prophylaxis). Dosing regimens are not standardized and must be determined by a qualified healthcare professional.

Data on the use of Immunine in pregnancy and lactation are limited. Because uncontrolled bleeding poses a risk to both mother and fetus, the decision to use factor IX replacement therapy should be made after a careful risk‑benefit assessment by the treating physician. Women who are pregnant or nursing should discuss potential risks with their healthcare provider.

To request Immunine, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Immunine contains human coagulation factor IX and is administered intravenously, similar to other plasma‑derived or recombinant factor IX concentrates. Compared with some recombinant products, Immunine may have a comparable safety profile but specific differences in purity, half‑life, and manufacturing processes can influence dosing frequency and immunogenicity. Clinicians choose a product based on patient history, inhibitor status, and therapeutic goals.

Immunine must be stored at 2‑8 °C (refrigerated). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If the product reaches room temperature for a short period during administration, it should be returned to the refrigerator promptly and used within the time frame specified by the manufacturer.

Immunine is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and volume are determined by the prescribing clinician based on the prescribed dose and the patient’s vascular access. Monitoring for infusion‑related reactions is recommended during and after the administration.

The most serious adverse events associated with Immunine include severe allergic reactions such as anaphylaxis, the development of neutralizing antibodies (inhibitors) that reduce treatment efficacy, and thrombotic complications like deep‑vein thrombosis. Additionally, because the product is derived from human plasma, there is a theoretical risk of viral transmission, although manufacturing processes aim to minimize this risk.

Immunine is contraindicated in individuals with a known hypersensitivity to human coagulation factor IX, any component of the formulation, or a history of severe allergic reactions to similar products. Patients with active, uncontrolled thrombosis should avoid use until the condition is stabilized. Use in patients with uncertain inhibitor status should be guided by specialist assessment.